At a glance
- Originator Pharmacia Corporation
- Class Antibacterials; Rifamycins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mycobacterium avium complex infections
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 05 Dec 1997 Preclinical development for Mycobacterium avium complex infections in USA (Unknown route)